Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 1, 2008, Pages 32-42

  Gumbo, T ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antimicrobial; Monte Carlo simulations; Pharmacodynamic; Pharmacogenomic; Pharmacokinetic; Single nucleotide polymorphism

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOKINE; DAPTOMYCIN; ETHAMBUTOL; FERRITIN; GLYCOPROTEIN P; INTERLEUKIN 1BETA; IRON; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; PROTON PUMP INHIBITOR; PYRAZINAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; DRUG DOSE INCREASE; DRUG RESPONSE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MUSCLE DISEASE; NEPHROTOXICITY; PHARMACODYNAMICS; PHARMACOGENOMICS; PREDICTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROBIAL SENSITIVITY TESTS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 37849025033     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Drusano GL, Johnson DE, Rosen M, Standiford HC: Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother (1993) 37(3):483-490.
2. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN et al: Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest (2003) 112(2):275-285.
3. Wallis RS, Patil S, Cheon SH, Edmonds K, Phillips M, Perkins MD, Joloba M, Namale A, Johnson JL, Teixeira L, Dietze R et al: Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (1999) 43(11):2600-2606.
4. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S: Bacterial persistence as a phenotypic switch. Science (2004) 305(5690):1622-1625.
5. Wiuff C, Zappala RM, Regoes RR, Garner KN, Baquero F, Levin BR: Phenotypic tolerance: Antibiotic enrichment of non-inherited resistance in bacterial populations. Antimicrob Agents Chemother (2005) 49(4):1483-1494.
6. Eagle H, Fleischman R, Levy M: "Continuous" vs "discontinuous" therapy with penicillin: The effect of the interval between injections on therapeutic efficacy. N Engl J Med (1953) 248(12):481-488.
7. Eagle H, Fleischman R, Musselman AD: Effect of schedule of administration on the therapeutic efficacy of penicillin: Importance of the aggregate time penicillin remains at effectively bactericidal levels. Am J Med (1950) 9(3):280-299.
8. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA: Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis (1988) 158(4):831- 847.
9. Craig WA: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 26(1):1-10.
10. Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, Drusano GL: Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis (2007) 195(2):194-201.
11. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL: The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: A new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother (2007) 51(2):744-747. •• Describes a study examining the effect of quinolone exposure on several species of bacteria, which established that the relationship between antimicrobial exposure and the drug-resistant subpopulation was best described by an inverted U curve. This relationship has the potential to be used to determine the drug exposure that suppresses resistance.
12. max/MIC was also established.
13. Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN, Drusano GL: Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis (2007) 195(12):1818-1827. •• Describes an elegant study which demonstrated that the duration of exposure is an important parameter in the development of drug resistance. Longer durations of therapy eventually lead to the emergence of drug resistance.
14. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL: Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clin Infect Dis (2007) 44(1):79-86.
15. max/MIC ratio as partly the result of concentrationdependent rapid entry of rifampin into M tuberculosis.
16. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Kantharaj E, Balasubramanian V: Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2004) 48(8):2951- 2957.
17. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, Lin Y et al: The diploid genome sequence of an individual human. PLoS Biol (2007) 5(10):e254. •• Describes a study in which the genes from one individual were sequenced to demonstrate the extent of genetic variability in humans.
18. Moyo VM, Mandishona E, Hasstedt SJ, Gangaidzo IT, Gomo ZA, Khumalo H, Saungweme T, Kiire CF, Paterson AC, Bloom P, MacPhail AP et al: Evidence of genetic transmission in African iron overload. Blood (1998) 91(3):1076-1082.
19. Gangaidzo IT, Moyo VM, Mvundura E, Aggrey G, Murphree NL, Khumalo H, Saungweme T, Kasvosve I, Gomo ZA, Rouault T, Boelaert JR et al: Association of pulmonary tuberculosis with increased dietary iron. J Infect Dis (2001) 184(7):936-939.
20. Lounis N, Maslo C, Truffot-Pernot C, Grosset J, Boelaert RJ: Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. Int J Tuberc Lung Dis (2003) 7(6):575-579. • Describes an important study that examined the effect of iron overload on the pharmacodynamics of anti-TB drugs, and confirmed results from the clinical study conducted by Gangaidzo et al, which suggested an association between iron overload and failure of anti-TB therapy.
21. Kasvosve I, Gomo ZA, Mvundura E, Moyo VM, Saungweme T, Khumalo H, Gordeuk VR, Boelaert JR, Delanghe JR, De Bacquer D, Gangaidzo IT: Haptoglobin polymorphism and mortality in patients with tuberculosis. Int J Tuberc Lung Dis (2000) 4(8):771-775.
22. Sohn DR, Kwon JT, Kim HK, Ishizaki T: Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status. Clin Pharmacol Ther (1997) 61(5):574-582.
23. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T: Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther (2001) 70(5):484-492.
24. Truffot-Pernot C, Ji B, Grosset J: Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother (1991) 35(8):1677- 1678.
25. Furuta T, Shirai N, Xiao F, El-Omar EM, Rabkin CS, Sugimura H, Ishizaki T, Ohashi K: Polymorphism of interleukin-1β affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol (2004) 2(1):22-30.
26. Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T: Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clin Pharmacol Ther (2006) 80(1):41-50. •• Describes a study which provides perhaps the best example of the effects of human genetic SNPs on pharmacokinetics and microbial response, and discusses how these SNPs interact to determine therapeutic outcome.
27. Müller M, dela Peña A, Derendorf H: Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Distribution in tissue. Antimicrob Agents Chemother (2004) 48(5):1441-1453.
28. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M: Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. J Am Med Assoc (1998) 279(2):125- 129.
29. Chow AT, Chen A, Lattime H, Morgan N, Wong F, Fowler C, Williams RR: Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses. J Clin Pharm Ther (2002) 27(2):143-150.
30. Conte JE Jr, Golden JA, McIver M, Zurlinden E: Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents (2006) 28(2):114-121.
31. Wagenlehner FM, Kinzig-Schippers M, Sörgel F, Weidner W, Naber KG: Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents (2006) 28(6):551-559.
32. Chien SC, Wong FA, Fowler CL, Callery-D'Amico SV, Williams RR, Nayak R, Chow AT: Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother (1998) 42(4):885-888.
33. Gonzalez FJ, Nebert DW: Evolution of the P450 gene superfamily: Animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet (1990) 6(6):182-186.
34. Weiner M, Burman W, Luo CC, Peloquin CA, Engle M, Goldberg S, Agarwal V, Vernon A: Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother (2007) 51(8):2861-2866. • Describes a study which investigated drug-drug interactions, which are a known cause of pharmacokinetic variability, in the context of gene polymorphisms, to demonstrate that rifampin has a potentially deleterious effect on moxifloxacin drug concentrations in certain populations.
35. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US: Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol (2006) 62(9):727-735.
36. Liu CH, Peck K, Huang JD, Lin MS, Wang CH, Hsu WP, Wang HW, Lee HL, Lai ML: Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics (2005) 6(7):731-747.
37. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther (2000) 67(1):48-56.
38. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J: Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther (1999) 66(3):288-294.
39. Nijland HM, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van CR, Aarnoutse RE: Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis (2007) 45(8):1001-1007.
40. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL: Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis (2004) 190(9):1642-1651.
41. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V: Moxifloxacin, ofloxacin, sparfloxacin and ciprofloxacin against Mycobacterium tuberculosis: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother (2007) 51(2):576-582. • Describes an important study establishing the PK-PD index that is best associated with fluoroquinolone optimal effects in mice infected with M tuberculosis.
42. Ji Y, Moon I, Zlatkovic J, Salavaggione OE, Thomae BA, Eckloff BW, Wieben ED, Schaid DJ, Weinshilboum RM: Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: Gene sequence variation and functional genomics. J Pharmacol Exp Ther (2007) 322(2):529-540.
43. Hildebrandt MA, Carrington DP, Thomae BA, Eckloff BW, Schaid DJ, Yee VC, Weinshilboum RM, Wieben ED: Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J (2007) 7(2):133-143.
44. Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA: Use of preclinical data for selection of a phase II/ III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother (2001) 45(1):13-22.
45. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW: Population pharmacokinetic modeling of isoniazid, rifampin and pyrazinamide. Antimicrob Agents Chemother (1997) 41(12):2670- 2679.
46. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, Tam CM, Kam KM, Lam CW, Sole KM, Mitchison DA: A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother (2000) 45(6):859-870.
47. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL: Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother (1999) 43(7):1549-1555.
48. Tedesco KL, Rybak MJ: Daptomycin. Pharmacotherapy (2004) 24(1):41-57.
49. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL: Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother (2001) 45(3):845-851.
50. Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP: Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother (2000) 44(11):2948-2953.
51. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH et al: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med (2006) 355(7):653-665.